An interventional study of Ultrasound treatment of Calcified aortic valve in Aortic Valve Stenosis, sponsored by Cardiawave SA. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Cardiawave SA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.
Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 62nd largest by enrollment of the 69 interventional ones that give a count, is one of 13 that started in 2019, is one of 58 with no phase, and was the 82nd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Ceric Sàrl · Sites in France, Austria, Estonia and 11 more countries
Ages 65–75
Hospices Civils de Lyon · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 20 more countries
Ages 6–11
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 1
First in 2002; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 186 across the 69 interventional studies, 470 across the 62 observational. Of the 79 that completed or were terminated, 13 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 131 have an industry lead sponsor. The 10 most frequent:
Cardiawave SA is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Cardiawave SA has 5 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT03728049University Hospital, LilleVon Willebrand Factor Point-of-care Testing to Improve Minimally Invasive TAVI Outcomes | 2026-12 |
| NCT02972008University Hospital, LilleIdentification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 131 studies in Aortic Valve Stenosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-man
CARDIAWAVE has developed a new non-invasive, real-time image-guided, therapeutic approach to treat patients suffering from Calcified Aortic Stenosis. CARDIAWAVE's Valvosoft device is a new ultrasound therapy based on a disruptive technology involving delivering an extremely precise and focused ultrasound beam to perform a reparative effect on the aortic valve leaflets, softening the valve's tissues, restoring leaflet mobility, and therefore improving the overall clinical status related to the aortic valve stenosis. This is a FIM study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
Exclusion Criteria:
Subjects who are participating in another research study for which the primary endpoint has not been reached.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
Device: Ultrasound treatment of Calcified aortic valve
Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
Safety: Rate of procedure related mortality at 30 days
Rate of procedure related mortality at 30 days
Time frame: 30 days post-procedure
Device performance to modify valve structure as measured by echocardiography
Ability to modify the Aortic Valve Area (mm2)
Time frame: Immediately post-procedure
Device performance to modify valve structure as measured by echocardiography
Ability to modify the Pressure Gradient (mmHg)
Time frame: Immediately post-procedure
All-cause mortality and major adverse events (MAE's)
Rate of all-cause mortality and MAE's peri and postprocedure and at 1, 3, 6, 12 and 24 months post operatively.
Time frame: Up to 24 months
Non-disabling stroke
Rate of stroke at 1,3,6, 12 and 24 months
Time frame: Up to 24 months
Improvement of clinical status
Improvement of New York Heart Association class (I-IV - stage of severity of heart failure - I=no symptoms, IV= symptoms at rest) at 1,3,6,12, and 24 months.
Time frame: Up to 24 months
Number of all Adverse Events (AEs)
Rate of AE's reported at at 1, 3, 6, 12 and 24 months
Time frame: Up to 24 months
User handeling of Valvosoft
User handling (questionnaire for operator + procedure duration) immediately post-procedure
Time frame: Immediately post-procedure
Improvement of quality of life
Improvement of quality of life by means of Kansas City Cardiomyopathy Questionnaire at 1, 3, 6, 12 and 24 months
Time frame: upto 24 months
Long term maintenance of improvement of AVA and PG
Long term maintenance of improvement of AVA and PG at 3, 6, 12 and 24 months
Time frame: upto 24 months
Plan to share: No
Ran from Mar 2019 to primary completion in Jan 2022, 34 months.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 34 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiawave SA